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Abstract
Background: TB and HIV are public health problems, which have a synergistic effect to each other. Despite the
decreasing burden of these two diseases they still make a significant contribution to mortality. Tanzania is among
the 30 high TB and HIV burden countries.
Methods: Routine data over 6 years from people living with HIV (PLHIV) attending health facilities in three regions
of Northern Tanzania were analyzed, showing mortality trends from 2012 to 2017 for HIV and HIV/TB
subpopulations. Poisson regression with frailty model adjusting for clustering at health facility level was used to
analyze the data to determine mortality rate ratios (RR) and 95% confidence intervals (95%CI).
Results: Among all PLHIV the overall mortality rate was 28.4 (95% CI 27.6–29.2) deaths per 1000 person-years. For
PLHIV with no evidence of TB the mortality rates was 26.2 (95% CI 25.4–27.0) per 1000 person-years, and for those
with HIV/TB co-infection 57.8 (95% CI 55.6–62.3) per 1000 person-years. After adjusting for age, sex, residence, WHO
stage, and bodyweight, PLHIV with TB co-infection had 40% higher mortality than those without TB (RR 1.4; 95% CI
1.24–1.67).
Conclusions: Over the 6-year period mortality rates for HIV/TB patients were consistently higher than for PLHIV
who have no TB. More efforts should be directed into improving nutritional status among HIV patients, as it has
destructive interaction with TB for mortality. This will improve patients’ body weight and CD4 counts which are
protective against mortality. Among PLHIV attention should be given to those who are in WHO HIV stage 3 or 4
and having TB co-infection.
Keywords: Tuberculosis, HIV, Tanzania, Mortality rates, sub-Saharan Africa
Introduction
TB and HIV are public health problems, which have a
synergistic effect to each other. In people living with
HIV (PLHIV), TB increases HIV replication and viral
heterogeneity [17, 18, 26, 36]. HIV on the other hand
lowers the immunity against TB leading to increased ac-
tive TB infection, re-infection, or reactivation. It also in-
creases the risk of TB progression from latent TB to
active TB disease [9, 10, 12, 27, 33]. The burden of TB
in countries with a high HIV prevalence, like Tanzania,
is substantial. Globally, over the last two decades, the in-
cidence of TB has declined from an incidence of 172
cases per 100,000 populations in year 2012 to 132 cases
per 100,000 in year 2018 probably due to increased
coverage and efficient TB management, HIV awareness
and widespread use of antiretroviral therapy (ART) [13,
42]. Early TB diagnosis, especially with the advent of
molecular diagnostic tests at HIV clinics, has led to early
TB treatment, which has contributed to reducing mor-
tality rates for TB, even in high HIV settings [37, 40].
Education on TB, and good collaborative HIV and TB
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activities, with increased use of Isoniazid Preventive
Therapy (IPT) among PLHIV, have also contributed to
reduced mortality rates [6, 19, 28, 39].
HIV and TB make a significant contribution to mortal-
ity with 770,000 people dying of AIDS related causes in
2018 and 1.6 million people dying of TB in 2017, with
300,000 deaths among those with HIV/TB co-infection
[38, 41]. Sub-Saharan Africa (SSA) accounts for 71% of
the global HIV/TB burden, and Tanzania is among the
30 countries with the highest burden of TB and HIV
[42]. HIV/TB co-infected patients have 1.8 times higher
risk of mortality compared to those who are HIV-
infected TB-free patients [4]. The odds of mortality are
3.5 times higher when the patients have HIV/Drug Re-
sistant Tuberculosis co-infection [23]. In 2018, Tanzania
reports showed that there were 22,000 deaths among
HIV negative TB patients and 16,000 deaths among HIV
positive patients co-infected with TB [42]. HIV/TB treat-
ment success rate is only 85% in Tanzania, meaning the
remaining 15% have poor treatment outcomes [41].
Factors that have been associated with increased mor-
tality among HIV/TB co-infected patients include low
CD4 count, WHO HIV stages 3 or 4, not receiving ART,
and not being on cotrimoxazole prophylaxis therapy
(CPT), being female sex worker, older age and being
bed-ridden [1, 32, 35]. Factors that have been associated
with mortality among HIV-positive TB-negative patients
include WHO HIV stage 3 or 4, older age, low CD4
counts, low hemoglobin, low educational status, body-
weight, as well as low adherence to ART [5, 8, 29, 30].
These factors have shown to differ between settings.
The World Health Organization (WHO)’s End TB
Strategy goal is to reduce the number of TB deaths by
35% in 2020 and by 90% by 2030 [42]. Although there
has been a reduction in TB deaths by only 11% globally
and 16% in the African region TB deaths Tanzania is on
track to achieve this milestone with a 30% reduction
[42]. Many studies have reported risk factors for mortal-
ity in PLHIV and PLHIV who are co-infected with TB.
However it is not yet known how mortality rates for
PLHIV, and PLHIV who are co-infected with TB, have
changed over time, and whether the factors associated
with mortality differ between those co-infected with TB
and those who are not TB infected [42].
This study aimed to compare trends of mortality for
HIV and HIV/TB subgroups over six-year period, from
2012 to 2017. Hence, describing the transition period
from the era of Millennium Development Goals (MDGs)
to Sustainable Development Goals (SDGs). It will inform
policy makers on the magnitude of the problem and en-
able them to devise potential interventions to tackle it.
The study has used routinely collected data from a big
database maintained by the Ministry of Health Commu-
nity Development Gender Elderly and Children
(MoHCDGEC) which will enable different insights to
other studies on HIV/TB mortality.
Methods
Study design and settings
This was a retrospective cohort using routinely collected
data on PLHIV attending HIV services at health facilities
from 1st January 2012 to 31st December 2017 from the
three regions of Northern Tanzania, namely, Arusha,
Tanga, and Kilimanjaro. HIV services are provided in
Care and Treatment Centres (CTCs) which enrol PLHIV
following HIV diagnosis, provide ART, and monitor pa-
tient progress. In Tanzania, PLHIV are expected to at-
tend CTC every month for a check-up and to receive
their ART and other medication. A standardized
MoHCDGEC-authorized individual CTC patient record
is completed on every occasion the PLHIV visits the
CTC. In this analysis, data came from CTC at all levels
(dispensary, health centres and hospitals) and from both
private and public facilities in three regions of Tanzania.
At every visit TB screening is undertaken and those
positive undertake further tests to make a confirmed TB
diagnosis [21, 22, 24]. This study used the individual pa-
tient records from all CTC that entered patient visit data
into the national CTC national database.
Study population
All PLHIV attending CTCs in these three regions who
were 15 or more years of age, and attended for care be-
tween 1st January 2012 to 31st December 2017, were eli-
gible for inclusion in this analysis.
Study variables
The individual CTC patient record routinely collects
data at enrollment on age, sex, marital status, weight,
nutritional status WHO HIV clinical stage and func-
tional status. Functional status has three categories:
those capable of working, those who cannot work but
are ambulatory, and those who are bedridden. Nutri-
tional status was subjectively evaluated by the health
care worker, who categorized patients into three cat-
egories: normal, moderate, or severe under-nutrition. At
each visit to the CTC, the patient record is used to rec-
ord details on the ART regime, using defined MoHCD-
GEC codes and categorized into first-line and second-
line ART regimes for the purpose of this analysis. CD4
counts were taken when needed, but were discontinued
in 2016 when viral load measurements were recom-
mended for monitoring patient progress.
Data analysis
After data were de-identified and cleaned, they were an-
alyzed using statistical software package, STATA 15.
Categorical data were summarized as frequencies and
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percentages. Continuous variables were summarized
using median and interquartile range (IQR) or using
mean and standard deviation. The key dependent vari-
able was mortality from any cause. The start time for
the person-time at risk was taken to be from 1 January
2012 or date of first enrollment at CTC (if that was later
that 1 January 2012). End study time was defined as the
date of death of any cause, or for those who did not die,
the date last seen at CTC, or 31 December 2017 if they
attended CTC after that date. TB diagnosis was defined as
having a record for starting anti-TB medications. Patients
who were positive to the TB screening questions, but did
not have a confirmed TB diagnosis were defined as non-TB
cases. A confirmed diagnosis could be made through chest
radiography, microbiology culture, PCR (eg GeneXpert) or
clinical judgement [25]. In Tanzania, PLHIV are treated
with triple therapy composed of either 2 of any Nucleoside
Reverse Transcriptase Inhibitors (NRTIs) and 1 Non-
Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), or
2 NRTIs and 1 Protease Inhibitors (PIs).
Mortality rates among HIV patients and HIV/TB pa-
tients over a period of 6 years were determined for dif-
ferent socio-demographic and clinical characteristics.
Variables with few missing data were analyzed as
complete case records, while for CD4 count and nutri-
tional status, which had more than 10% missing data, a
restricted analysis was performed for each variable sep-
arately (Fig. 1). The trends of mortality from 2012 to
2017 were determined and compared between HIV and
HIV/TB subpopulations. Cluster level analysis using
(analysis of variance) ANOVA was done to determine
the effects of health facilities on HIV mortality. Poisson
regression models were used to determine rate ratios
(RR) and 95% confidence intervals (95%CI), with a
multilevel fraility component to adjust for clustering by
health facility. Finally, Poisson regression models with
frailty were used to determine the interactions between
TB co-infection and other factors on mortality among
PLHIV.
Results
The study involved 88,934 patients who were HIV posi-
tive, of which 83,489 (93.9%) had no TB co-infection
and 5,446 (6.1%) had HIV/TB co-infection at some stage
over the 6 years. There were 25,618 (28.8%) male pa-
tients and 29,007 (32.6%) were aged between 35 and 44
years of age when they were started to be followed up.
Among those who had their CD4 count measured, 17,
835 (63.7%) of them had CD4 count below 350 cells/ul.
Most patients were from Tanga, 45,095(50.7%) than
from Arusha or Kilimanjaro regions (Table 1).
A total of 4757 HIV-positive patients died during 167,
700 person-years of follow-up, giving the overall mortal-
ity rate of 28.4 (95% CI 27.6–29.2) per 1000 person-
years. The mortality rate was 26.2 (95% CI 25.4–27.0)
per 1000 person-years among PLHIV who had no TB,
and 57.8 (95% CI 53.6–62.3) per 1000 person-years
among those with HIV/TB co-infection (Table 1). The
highest mortality rates were among patients who were
ambulatory (Mortality rate of 135.6 (95% CI 108.6–
Fig. 1 The study’s flow diagram
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Table 1 Mortality rates by sociodemographic and clinical characteristics at enrolment into HIV services for PLHIV patients in three
regions of Northern Tanzania (N = 88,934)
Number of PLHIV
(%)
Number of deaths for all PLHIV
(%)
Person-years of follow-up (in 1000
years)
Mortality rate per 1000 for PLHIV (95%
CI)
Characteristics 88,934 4,757 (5.3) 167.7 28.4 (27.6–29.2)
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169.3) per 1000 person-years), had severe under-
nutrition (125.6 (95% CI 95.9–164.3) per 1000 person-
years), bedridden (79.5 (95% CI 64.6–76.9) per 1000
person-years) and with moderate under-nutritional (60.6
(95% CI 55.5–66.1) per 1000 person-years).
HIV/TB co-infected patients had a mortality rate of
177.3 (95% CI 111.7–281.5) per 1000 person-years in 2012
which declined to 31.5 (95% C1 19.8–49.9) per 1000
person-years in 2016 and 53.3 (95% CI 34.7–81.7) per
1000 person-years in 2017. For PLHIV who had no TB
history mortality rates also declined from 38.2 (95% CI
35.7–40.8) per 1000 person-years in 2012 to 18.3 (95%CI
16.7–20.1) per 1000 person-years in 2017 (Fig. 2).
Using ANOVA analysis on the mortality rates by
health facilities showed differences across health facility
types. PLHIV attending health centers and hospitals had
higher mortality rates than those attending a dispensary
(Table 2). Mortality among PLHIV attending private fa-
cilities was higher than those attending a public health
facility. There was also differences between the regions
with the highest mortality in Arusha region (41 deaths
per 1000 person-years) and the lowest in Tanga region
(33 patients deaths per 1000 person-years) (Table 2).
A Poisson regression model controlling for age, sex,
bodyweight, WHO HIV stage, region, functional status,
and TB status with a multilevel component analysis
using health facility as the cluster variable was used
(Table 3). Compared to those aged 15–24 years higher
mortality was observed among PLHIV aged between 35
and 44 years (RR = 1.30, 95%CI 1.05–1.61) and those
aged above 55 years (RR = 1.88, 95%CI 1.50–2.37).
Those with moderately (RR = 1.61, 95%CI 1.39–1.85)
and severely (RR = 1.90, 95% CI 1.24–2.90) poor nutri-
tional status had higher mortality compared to those
with normal nutritional status. Conversely, lower mortal-
ity was observed among females (RR = 0.62, 95% CI
0.56–0.69) compared to males, body weight between 40
and 60 kg (RR = 0.50, 95%CI 0.43–0.58) and above 60
kg (RR = 0.26, 95%CI 0.22–0.31) compared to those
under 40 kg in weight. A lower mortality was observed
in Tanga region (RR = 0.78, 95% CI 0.69–0.91) com-
pared to Arusha. PLHIV with TB co-infection had
higher mortality (RR = 1.4, 95%CI 1.24–1.67) compared
to those who had not experienced TB infection.
There were interactions between TB and other inde-
pendent variables with weaker evidence of differences in
mortality among PLHIV who had TB compared to the
rate ratios in PLHIV who did not experience TB (Table 4).
The interaction was statistically significant for WHO HIV
stage (p value = 1.49, 95% CI 1.01–2.19) and nutritional
status (based on the subset of the data with nutritional sta-
tus recorded). Among PLHIV co-infected with TB, those
residing in Kilimanjaro region (RR = 0.63, 95%CI 0.46–
0.86), and in Tanga Region (RR = 0.61, 95%CI 0.48–0.78)
had lower mortality compared to Arusha region, and these
effects were bigger than the effects seen in PLHIV who
did not have TB.
Discussion
Mortality among PLHIV co-infected with TB is 1.4 times
higher than in PLHIV who do not have TB. Since 2012
this increased mortality rate ratio has persisted for every
year, although mortality rates for both groups have de-
clined consistently since 2012. In PLHIV without TB
mortality rates have declined by 52% over the 6 years
from 38.2 deaths per 1000 person-years in 2012 to 18.2
deaths per 1000 person-years in 2017. In PLHIV co-
infected with TB mortality has declined by 70% over the
6 years from 177.3 deaths per 1000 person-years in 2012
to 53.3 deaths per 1000 person-years in 2017. WHO re-
ports have shown similar declines in mortality in other
high TB burden countries, such as Central African Re-
public, Congo, Kenya, Liberia, Mozambique, Namibia,
and Thailand [42]. The provision of ART for PLHIV has
been very effective in reducing mortality, and PLHIV co-
infected with TB have benefited more from these inter-
ventions as they had a higher mortality to start with.
The mortality in PLHIV co-infected with TB is greater
than mortality in PLHIV without TB in every subgroup
analyzed, with a Crude Rate Ratio for TB co-infected pa-
tients of 2.23. The mortality rates showed evidence of
clustering by health facility, and a fraility model was fit-
ted to adjusting for that clustering. The higher mortality
rate ratio for PLHIV co-infected with TB persisted to be
2.2 times higher compared to those with TB co-infection
after adjusting for health facility clustering. However, the
effect was confounded by functional status and region,
and after controlling for these and other factors the rate
ratio decreased to around 1.4 times higher compared to
those with no TB co-infection. This change may be
Fig. 2 Trends of mortality over the years per 1000 person-years for
HIV and HIV/TB co-infected patients
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partly due to the effect TB has on the functional status
of PLHIV.
The significant reduction in mortality among PLHIV
observed from 2012 to 2016 is probably due to increas-
ing use of ART [22, 24]. UNAIDS reported in 2017 that
in Northern Tanzania there had been only 10% reduc-
tion in TB mortality (from 63.1 death per 1000 person-
years in 2015 to 53.3 deaths per person-years), but over
the whole of Tanzania the reduction was between 25
and 49% [38]. The United Nation high level meeting
conducted in 2016 set the target of reducing TB deaths
among HIV patients by 35% in 2020 using 2015 data as
baseline data [38]. As many TB deaths are contributed
by PLHIV co-infected with TB, a delay or slow reduction
in mortality in this group could negatively affect the
achievement of other targets set by the WHO through
the WHO End TB Strategy. The WHO End TB Strategy
aims to reduce the absolute number of deaths due to TB
by 35% by the end of 2020 [42]. Recent WHO data have
also shown that Tanzania as a whole is on track to
achieve this milestone as well [42].
In addition, isoniazid prevention therapy (IPT) to pre-
vent TB infection was introduced in Tanzania in the late
2011 [28]. Increasing ART coverage among PLHIV has
the potential to decrease TB progression among those
co-infected with TB [2]. The introduction of a molecular
diagnostic test, GeneXpert MTB/RIF, in 2013, which has
high accuracy, has helped early TB detection and has fa-
cilitated early treatment initiation [22–24, 34, 40]. In-
creased awareness of TB and improved health systems
to deal with TB infection are other important factors
that have contributed to this success [6, 19].
Among study population, mortality rates were higher
for patients with severely poor nutritional status, bed-
ridden patients, and ambulatory patients. Similar find-
ings have been observed in Dar es Salaam and Manyara
in Tanzania, and in Cameroon and Ethiopia [7, 16, 20,
31]). Poor nutrition on the other hand is a risk factor for
TB incidence among HIV patients, leading to a fatal vi-
cious cycle [22, 24].
The study has also found that more deaths among
HIV-positive patients are observed in hospitals and
health centers compared to dispensaries. This can be at-
tributed to the referral mechanism in the country,
whereby patients with poor prognosis at the dispensary
(which is a lower level facility) will always be referred to
health center or hospital for further advanced manage-
ment. Also, most seriously sick patients go to the hospi-
tals and this is expected to increase the number of
deaths in the hospitals. More deaths were observed in
private hospitals than public hospitals, probably because
most private facilities are hospitals rather than dispens-
aries. Regional differences in mortality rates can be at-
tributed to several geographical inequalities (such as
access to health facilities, availability of adequate health
care providers, health seeking behaviors, etc.) despite the
availability of the national guidelines and roll out of HIV
and TB service. The contextual difference can be appre-
ciated by the cluster effects which show that more than
6% of the variability in mortality is due to differences be-
tween health facilities across the different regions.
Several factors that have been associated with mortal-
ity among HIV patients have been observed elsewhere.
Age above 55 years, HIV stage 3 and 4, and poor
Table 2 Comparison of cluster level’s mortality rates per 1000 person-years among PLHIV in 253 health facilities in three regions of
Northern Tanzania (N = 88,934)
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Table 3 Poisson regression with multilevel analysis (health facility as cluster variable) of the determinants of mortality rates among
PLHIV in Northern Tanzania (N = 82,925)




Adjusted rate ratio (95%CI) adjusting only
for clusters
ARR (95% CI) adjusting for other factors and
for clusters *
Age
15–24 258 7812 1 1 1
25–34 853 22,795 1.03 (0.90–1.19) 1.06 (0.92–1.22) 1.21 (0.97–1.51)
35–44 1600 27,407 1.14 (1.00–1.31) 1.17 (1.03–1.34) 1.30 (1.05–1.61)
55–55 1147 15,759 1.21 (1.05–1.39) 1.24 (1.08–1.43) 1.23 (0.98–1.54)
Above 55 899 7520 1.90 (1.64–2.19) 1.92 (1.66–2.21) 1.88 (1.50–2.37)
Sex
Male 1906 23,712 1 1 1
Female 2851 60,465 0.57 (0.54–0.60) 0.57 (0.54–0.60) 0.62 (0.56–0.69)
HIV WHO stage
Stage 1 482 21,756 1 1 1
Stage 2 940 18,974 1.45 (1.30–1.61) 1.51 (1.36–1.68) 1.38 (1.13–1.69)
Stage 3 2091 30,257 1.74 (1.59–1.92) 1.90 (1.73–2.09) 1.58 (1.32–1.90)
Stage 4 1159 10,801 2.70 (2.43–2.99) 3.01 (2.75–3.39) 2.08 (1.71–2.54)
Region
Arusha 517 13,799 1 1 1
Kilimanjaro 1293 28,231 0.73 (0.66–0.80) 0.76 (0.69–0.85) 0.88 (0.74–1.03)
Tanga 2946 42,148 0.93 (0.85–1.02) 0.95 (0.87–1.04) 0.78 (0.69–0.91)
Functional status
Bedridden 503 3696 1 1 1
Ambulatory 78 512 1.90 (1.51–2.39) 1.96 (1.56–2.47) 3.59 (2.39–5.39)
Working 4152 79,342 0.38 (0.34–0.41) 0.38 (0.35–0.42) 0.56 (0.47–0.68)
TB status
No TB 4085 79,403 1 1 1
TB Co-
infection
671 4775 2.23 (2.06–2.41) 2.25 (2.08–2.44) 1.4 (1.24–1.67)
Nutritional status **
Ok 3237 60,389 1 1 1
Moderate 511 4332 2.11 (1.93–2.31) 2.06 (1.90–2.28) 1.61 (1.39–1.85)
Severe 53 342 4.06 (3.15–5.24) 4.15 (3.21–5.36) 1.90 (1.24–2.90)
Body weight***
Below 40 kg 691 7302 1 1 1
40–60 kg 3014 46,801 0.77 (0.72–0.83) 0.77 (0.72–0.83) 0.50 (0.43–0.58)
Above 60
kg
790 24,780 0.39 (0.35–0.42) 0.39 (0.36–0.43) 0.26 (0.22–0.31)
CD4 count****
Below 350 1479 16,356 1 1 1
350–500 157 4599 0.41 (0.35–0.48) 0.42 (0.36–0.49) 0.48 (0.39–0.58)
above 500 100 5322 0.31 (0.25–0.37) 0.31 (0.26–0.38) 0.40 (0.32–0.51)
*Adjusted for age, sex, region, WHO stage, functional status, TB status (N = 77,369)
**Adjusted for age, sex, region, WHO stage, functional status, TB status (N = 65,063)
***Adjusted for age, sex, region, WHO stage, functional status, TB status (N = 71,813)
****Adjusted for age, sex, bodyweight, region, WHO stage, functional status, TB status (N = 26,277)
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Table 4 Poisson regression with multilevel analysis, with health facility as cluster variable in Northern Tanzania. Interaction effects for
mortality among patients with HIV adjusted for the significant effects included in Table 3 (N = 82,925)
Characteristics ARR (95%CI) PLHIV without TB ARR (95%CI)
PLHIV/TB co-infection *
Effect of TB infection in baseline **
Age
15–24 1 2.06 (1.42–2.99)
25–34 1.27 (1.07–1.52) 0.97 (0.66–1.43)
35–44 1.36 (1.14–1.61) 0.91 (0.63–1.33)
45–55 1.34 (1.12–1.60) 0.93 (0.63–1.37)
Above 55 1.98 (1.65–2.37) 1.26 (0.84–1.90)
Sex
Male 1 1.41 (1.22–1.62)
Female 0.57 (0.53–0.61) 0.63 (0.53–0.75)
Body weight
Below 40 kg 1 0.89 (0.70–1.13)
40–60 kg 0.46 (0.42–0.52) 0.80 (0.62–1.02)
Above 60 kg 0.22 (0.20–0.26) 0.58 (0.42–0.80)
HIV WHO stage
Stage 1 1 1.49 (1.01–2.19)
Stage 2 1.35 (1.19–1.53) 1.53 (0.99–2.36)
Stage 3 1.50 (1.33–1.68) 1.42 (0.96–2.09)
Stage 4 2.22 (1.95–2.54) 1.74 (1.16–2.62)
Region
Arusha 1 2.02 (1.58–2.59)
Kilimanjaro 0.89 (0.77–1.03) 0.63 (0.46–0.86)
Tanga 0.86 (0.76–0.97) 0.61 (0.48–0.78)
Functional status
Bedridden 1 1.15 (0.90–1.48)
Ambulatory 2.57 (1.88–3.52) 1.11 (0.54–2.31)
Working 0.59 (0.52–0.67) 0.81 (0.64–1.03)
Nutritional status
Ok 1 1.61 (1.45–1.79)
Moderate 1.67 (1.50–1.86) 1.28 (1.03–1.61)
Severe 2.40 (1.71–3.35) 0.63 (0.35–1.12)
Year of follow-up
2012 1 1.36 (1.05–1.74)
2013 0.83 (0.74–0.93) 0.87 (0.63–1.20)
2014 0.73 (0.65–0.82) 0.91 (0.68–1.24)
2015 0.71 (0.64–0.80) 0.71 (0.52–0.97)
2016 0.56 (0.50–0.63) 0.46 (0.33–0.64)
2017 0.44 (0.38–0.51) 0.72 (0.51–1.01)
ARR adjusted rate ratio
Estimates of interaction effects are adjusted for age, sex, bodyweight, HIV WHO stage, region, functional status, and year of follow-up
*At non-baseline levels the effects are shown within each group (HIV alone and HIV/TB) comparing the level with the baseline level
**Adjusted rate ratios in the baseline level of each factor show the effect of TB on mortality at that baseline level
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nutritional status have been associated with HIV mortal-
ity in Ethiopia [30] and China [14]. Other studies have
found factors such as anemia and thrombocytopenia, de-
layed diagnosis, pneumonia as well as low adherence to
ARVs have contributed to higher mortality [11, 14, 16,
30]. In our study, CD4 count higher than 350 cell/ul,
body weight higher than 40 kg, and being female were
protective against HIV mortality, similar findings have
been observed elsewhere [3, 15].
For PLHIV, there were some interactions between TB
and all other independent factors for mortality. This
means that TB modifies the influence of these different
factors on mortality. However, all factors had interac-
tions with TB, but TB reduced the effect of functional
status and poor nutrition on mortality, probably as there
is a close correlation between these factors and TB
infection.
This study’s strength is it used programmatically and
routinely collected data from all health facilities in three
regions for six years. It was limited in that TB diagnosis
was defined as being on anti-TB treatment. With the po-
tential of having inadequate TB diagnostic tools espe-
cially in lower facilities as well as delay of starting TB
treatment since its detection, its very possible that the
number of HIV/TB cases have been underestimated.
Conclusions
Despite the study limitations, it shows that more efforts
are needed to reduce the mortality rates among HIV pa-
tients, especially those with TB co-infection. Efforts
should be directed into improving nutritional status and
functional status among HIV patients, and avoiding ad-
vanced HIV disease through early identification of those
infected and early use of ART. These factors are associ-
ated with higher mortality and are also risk factors for
TB incidence. Improved nutritional status will also im-
prove body weight and CD4 counts which are protective
against mortality.
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